Solifenacin

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Urinary Bladder, Overactive

Conditions

Urinary Bladder, Overactive

Trial Timeline

Jun 1, 2014 → Mar 1, 2016

NCT ID

NCT02087098

About Solifenacin

Solifenacin is a pre-clinical stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT02087098. Target conditions include Urinary Bladder, Overactive.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02087098	Pre-clinical	Completed	Jun 1, 2014	Mar 1, 2016	Urinary Bladder, Overactive
NCT01642277	Phase 2	Completed	Jul 1, 2012	Aug 1, 2014	Overactive Bladder
NCT01559389	Approved	Completed	Mar 9, 2012	Jun 29, 2017	Urge Urinary Incontinence
NCT01314781	Approved	Completed	Jan 1, 2012	Mar 1, 2015	Overactive Bladder
NCT01799902	Pre-clinical	Completed	Dec 1, 2011	Oct 1, 2013	Lower Urinary Tract Predominant Storage Symptoms
NCT01505439	Approved	Completed	Jun 1, 2011	Jun 1, 2014	Stress Urinary Incontinence
NCT01318837	Approved	Completed	Apr 1, 2010	Sep 1, 2011	Over Active Bladder
NCT02667470	Approved	Completed	Sep 1, 2009	May 1, 2013	Overactive Bladder
NCT01122563	Pre-clinical	Completed	Sep 1, 2009	Jan 1, 2011	Overactive Bladder
NCT00985387	Pre-clinical	Completed	Aug 1, 2009	Aug 1, 2011	Urinary Bladder, Overactive
NCT00979472	Approved	Completed	Apr 1, 2009	Jun 1, 2010	Urinary Bladder, Overactive
NCT00884104	Approved	Completed	Mar 1, 2009	Dec 1, 2010	Overactive Bladder
NCT00852696	Pre-clinical	Terminated	Feb 1, 2008	Feb 1, 2010	Overactive Bladder

Competing Products

20 competing products in Urinary Bladder, Overactive

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + placebo	Eli Lilly	Phase 2	52
Duloxetine	Eli Lilly	Phase 2	52
Enfortumab vedotin	Astellas Pharma	Phase 1	33
solifenacin succinate + tamsulosin + placebo	Astellas Pharma	Approved	85
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosin	Astellas Pharma	Phase 2	52
Solifenacin	Astellas Pharma	Approved	85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine	Astellas Pharma	Phase 3	77
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)	Astellas Pharma	Approved	85
solifenacin succinate	Astellas Pharma	Phase 3	77
Solifenacin	Astellas Pharma	Pre-clinical	23
Solifenacin	Astellas Pharma	Pre-clinical	23
Tamuslosin	Astellas Pharma	Phase 3	77
Tamsulosin + Solifenacin	Astellas Pharma	Approved	85
Alpha blocker + placebo + solifenacin	Astellas Pharma	Approved	85
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placebo	Astellas Pharma	Phase 3	77
solifenacin succinate + tolterodine	Astellas Pharma	Phase 3	77
Tamusulosin	Astellas Pharma	Phase 3	77
Solifenacin succinate + Tolterodine	Astellas Pharma	Phase 3	77
Solifenacin succinate + Placebo	Astellas Pharma	Phase 3	77
Vesicare	Astellas Pharma	Pre-clinical	23

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved